Press Releases & Company Updates

2016/03/04

WuXi AppTec’s STA Subsidiary Opens New Campus in Changzhou

SHANGHAI, March 4, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) began operations ata new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.

2016/02/15

WuXi AppTec Releases New Mobile App for Compounds Sourcing

SHANGHAI, February 15, 2016-- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of the LabNetwork mobile app. The first of its kind, the app gives chemists and sourcing professionals the ability to search a massive database of research chemicals, including novel building blocks, screening compounds, and more.

2016/02/02

WuXi AppTec Congratulates MSD on Receiving FDA Approval of ZEPATIER™

SHANGHAI, February 2, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, congratulates MSD, known as Merck & Co., Inc. in the United States and Canada, for receiving approval from the FDA for ZEPATIER™ (elbasvir / grazoprevir) for the treatment of adult patients with chronic hepatitis C virus, genotypes 1 or 4.

2016/01/08

WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group

SHANGHAI, January 8, 2016 -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

2015/12/10

WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction

WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the completion of its merger (the "Merger") with WuXi Merger Limited("Merger Sub"), a wholly-owned subsidiary of New WuXi Life Science Limited ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2015 and amended on October 20, 2015 and November 20, 2015, among the Company, Parent and Merger Sub. As a result of the Merger, Parent has acquired the Company (which is now a direct wholly owned subsidiary of Parent) in a cash transaction valued at approximately US$3.3 billion.